MeOmics Technology employs genomic sequencing and biomarker analysis to enhance the precision of mental health diagnoses and treatment plans. The company provides personalized insights that improve patient outcomes by overcoming the limitations of conventional diagnostic methods.
Funding
$190K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for diagnosing and treating mental health disorders often lack precision, leading to suboptimal patient outcomes. Traditional diagnostic approaches may not fully capture the complexity and heterogeneity of these conditions. The low success rate of psychiatric drug development further compounds the challenge of effective treatment.
Solution
MeOmics Precision Medicine Ltd has developed a platform that leverages patient-derived neuronal cell models, genomics, and AI/ML analysis to enhance precision in mental healthcare. The platform creates "brains on a chip" that act as "patient populations on a plate," enabling the discovery of novel biomarkers, biotypes, and therapeutic mechanisms. By integrating real neuronal signals, genomic data, and clinical insights, MeOmics aims to improve drug development outcomes and enable patient stratification, similar to how biomarkers have transformed oncology. This approach facilitates the development of targeted treatments tailored to individual patient needs, ultimately improving the efficiency and precision of psychiatric drug discovery and treatment selection.
Target Audience
MeOmics' primary customers include pharmaceutical companies, research institutions, and clinicians involved in psychiatric drug discovery and personalized mental healthcare.
Features
- Patient-derived neuronal cell models for preclinical screening
- Integration of genomics, phenomics, and cellomics data
- AI/ML-driven analysis for biomarker discovery and patient stratification
- Human cell-based neuronal network to enhance clinical translatability
- Computational interface for precise interaction with the central nervous system at the circuit level
- Capability to model drug responses using human-derived neurons